Dr. Schadendorf on the Efficacy of Targeted Therapy Plus Checkpoint Inhibitors
October 21st 2017Dirk Schadendorf, MD, head of department for Dermatology, Venerology and Allergology, University Hospital Essen, Germany, discusses the efficacy of combining targeted therapy with checkpoint inhibitors for patients with melanoma.
Read More
Dr. Schadendorf on Nivolumab/ Ipilimumab Combination Trial in Melanoma
November 27th 2015Dirk Schadendorf, MD, Head of Department for Dermatology, Venerology und Allergology, University Hospital Essen, Germany, discusses the results from the phase III CheckMate 067 study, which looked at a combination immunotherapy regimen in advanced melanoma.
Read More